Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma
NCT03387514Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piflufolastat f 18 in renal cell carcinoma (RCC), sponsored by University of Wisconsin–Madison. Primary endpoints: Baseline Tumor FDG PET SUV Data, Immunohistochemical Staining for PSMA at 24 months and 2 more. Started Dec 2018; status: terminated.
02
Drugs
piflufolastat f 18
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03387514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387514.